Literature DB >> 6130447

Dynorphin(1-10)amide: a potent and selective analog of dynorphin(1-13).

S Woo, J Garzon, P Sanchez-Blazquez, F C Tulunay, J K Chang, H H Loh.   

Abstract

Dynorphin(1-10)amide was more potent than Dynorphin(1-13) in inhibiting the twitch of the mouse vas deferens (IC50 of Dynorphin(1-10)amide = 0.3 nM and IC50 of Dynorphin (1-13) = 4.0 nM). Binding assays indicated that two opioid peptides had similar profiles in that they enhanced dihydromorphine (DHM) binding in picomolar concentrations but displaced DHM binding in nanomolar concentrations (IC50 for Dynorphin(1-10)amide = 5 nM). In the mouse tail-flick assay, however, Dynorphin(1-10)amide showed a more selective action on morphine-induced analgesia. Although Dynorphin(1-10)amide had no significant analgesic activity by itself, it differed from the (1-13) analog by neither potentiating nor antagonizing morphine in naive animals. In tolerant animals, on the other hand, 50 microgram of this analog administered icv shifted the ED50 of morphine from 43.0(33.0-55.9) to 17.0 (12.4-23.3). Thus, Dynorphin(1-10)amide appears to be a more potent and selective analog of Dynorphin(1-13).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130447     DOI: 10.1016/0024-3205(82)90218-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  [Biocytin13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor.

Authors:  G Hochhaus; A Patthy; R Schwietert; D V Santi; W Sadée
Journal:  Pharm Res       Date:  1988-12       Impact factor: 4.200

2.  Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.

Authors:  Brugos Brugos; Vikram Arya; Guenther Hochhaus
Journal:  AAPS J       Date:  2004-12-28       Impact factor: 4.009

3.  Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats.

Authors:  Suliman I Al-Fayoumi; Boglarka Brugos; Vikram Arya; Esther Mulder; Barbel Eppler; Andre P Mauderli; Günther Hochhaus
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.